Arius Research

ARIUS Research is a biotechnology company developing antibody therapeutics.

Business Model:

Revenue: $0

Employees: 11-50

Rankings

Detailed Arius Research Information

Arius Research was acquired by Roche.
The acquisition happend on 2008-07-22.
Details of the transaction were not public

Acquirer

Geographic Data

Arius Research headquarters map

Address:

City: Toronto

State: Ontario

Zip:

Country: Canada

Financial Info

Stage:

series unknown

Raised Last:

$22M

Raised Total:

$24M

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

ARIUS Research, Inc., a biotechnology company, engages in the discovery and development of antibody therapeutics primarily focusing on breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma. It identifies monoclonal antibodies targeting various cancer indications through its technology platform, FunctionFIRST. The company&s;s product pipeline includes CD63 program that is in preclinical studies for various cancer indications; ARH460-16-2, an antibody targeting the cancer stem cell antigen CD44; AR36A36.11.1 and AR10A304.7, which targets the complement-inhibitory molecule CD59; AR47A6.4.2 and AR52A301.5, which are monoclonal antibodies directed to the cancer-associated protein TROP-2 that is homologous to human EpCAM, an another cell surface cancer related protein; and AR40A746.2.3 that targets leukemia cancer stem cells. It also has antibody programs targeting the MCSP antigen and 37LRP. ARIUS has partnerships with Oxford BioMedica plc, Xerion Pharmaceuticals AG, PDL BioPharma, Inc., Medarex, Inc., Genentech, Inc., and Takeda Pharmaceutical Company Limited. The company was founded in 1999 and is based in Toronto, Canada. As of September 23, 2008, Arius Research Inc. operates as a subsidiary of Roche Holding AG.

Contact Phone:

Contact Email:

Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
3/2006 Venture Round 3 $21.5M Efficacy Capital
OrbiMed
Xmark Opportunity Funds
Efficacy Capital
OrbiMed
Xmark Opportunity Funds
11/2005 Venture Round 1 $2M Xmark Asset Management
Xmark Asset Management
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research